Replies to post #92410 on Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Now that the early NEO data was not good enough for Amgen to continue to support the tech and ADXS is adding a PD1, which is basically acknowledging NEO and HOT are nothing special compared to the zillion other competing treatments in development, the market is fairly valuing ADXS at present.